Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Signs Research Agreement With Shizuoka Prefecture Cancer Center

This article was originally published in PharmAsia News

Executive Summary

Osaka based AstraZeneca Japan signed an agreement Aug. 18 with the Shizuoka Prefecture Cancer Center to conduct basic research and clinical trials in an effort to develop new cancer drugs. According to the agreement, as the pharmaceutical company with the most cancer drugs in Japan, AstraZeneca will engage with center researchers starting from the drug candidate selection phase, and will use the feedback to speed up the developmental process of cancer drugs targeting Japanese and other Asian patients. It is the first such agreement between a global pharmaceutical company and a medical facility in Japan. (Click here for more - Japanese language) "The Shizuoka Prefecture Cancer Center Signs Development Agreement With Pharmaceutical Company" - Mainichi News (8/19/08)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069324

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel